Reports
Publicerat: 2019-10-22 08:25:00
Anders Karlsson, CEO
”With new strong patents being prepared, a solid scientific foundation and an organisation that has demonstrated high levels of competence, flexibility and efficiency, Idogen is now ready to take its tolerogenic cell therapies to clinical trials.”
Anders Karlsson, Chief Executive Officer Phone: +46 (0) 709 18 00 10 Email: anders.karlsson@idogen.com This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on August 23, 2019. Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient"s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.comTHIRD QUATER (JULY – SEPTEMBER 2019)
PERIOD (JANUARY – SEPTEMBER 2019)
SIGNIFICANT EVENTS IN THE THIRD QUARTER
SIGNIFICANT EVENTS DURING THE PERIOD
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD
CONDENSED EARNINGS AND CASH FLOW
2019
2018
2019
2018
2018
3 months
3 months
9 months
9 months
12 months
(Amounts in KSEK unless otherwise stated)
July-Sept
July-Sept
Jan-Sept
Jan-Sept
Jan-Dec
Net sales973
0
2 967
0
3 766
Operating expenses-7 726
-7 268
-27 789
-23 065
-31 627
Operating loss- 6 753
-7 268
-24 822
-23 065
-27 861
Loss for the period after net financial items-6 622
-7 318
- 24 487
-22 828
-27 634
Avarage number of shares48 491 533
20 781 790
48 491 533
20 779 833
21 843 166
Avarage number of warrants0
8 555 883
2 820 621
12 880 835
11 790 710
Loss per share before dilution (SEK)
-0,14 -0,35
-0,50
-1,10
-1,27
Loss per share after dilution (SEK)
-0,14 -0,35
-0,50
-1,10
-1,27
Cash flow from operating activities
-8 624 -6 860
-27 185
-9 961
-10 394
KEY FIGURES
Working capital21 760
8 532
21 760
8 532
42 306
Acid-test ratio (%)290
151
290
151
305
Equity/assets ratio (%)69
51
69
51
71
Loss per share before dilution-0,14
-0,35
-0,50
-1,10
-1,27
Average number of shares48 491 533
20 781 790
48 491 533
20 779 833
21 843 166
IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT: